Davis Polk is advising J.P. Morgan as financial adviser to Alere Inc. in connection with the amendment of the existing terms of its agreement for Abbott’s acquisition of Alere. Under the amended terms, Abbott will pay $51 per common share to acquire Alere, for a new expected equity value of approximately $5.3 billion. The transaction, which is expected to close by the end of the third quarter of 2017, is subject to the approval of Alere shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals.

Headquartered in Waltham, Massachusetts, Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare.

The Davis Polk corporate team includes partner Phillip R. Mills and associate Faizan A. Tukdi. All members of the Davis Polk team are based in the New York office.

Copy link to share post